BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-312@pharmaconomics
DTSTAMP:20260707T005012Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:MLTX Phase 3 — IZAR-1 (estimated date)
DESCRIPTION:Phase 3 trial results for IZAR-1 in psoriatic arthritis are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea029539901ex99-2.htm\n\nTrack it: https://www.pharmaconomics.com/e/312
URL:https://www.pharmaconomics.com/e/312
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MLTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR